Advanced search
Publication Cover
OncoTargets and Therapy Volume 10, 2017 - Issue
Submit an article Journal homepage
63
Views
11
CrossRef citations to date
0
Altmetric
Review

Immunotargeting relapsed or refractory precursor B-cell acute lymphoblastic leukemia – role of blinatumomab

Manon QueudevilleDepartment of Pediatric Hematology and Oncology, University Children’s Hospital, University of Tübingen, Tübingen, Germany
,
Rupert HandgretingerDepartment of Pediatric Hematology and Oncology, University Children’s Hospital, University of Tübingen, Tübingen, Germany
&
Martin EbingerDepartment of Pediatric Hematology and Oncology, University Children’s Hospital, University of Tübingen, Tübingen, GermanyCorrespondence[email protected]
Pages 3567-3578 | Published online: 19 Jul 2017

Citations (11)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Josep-Maria Ribera. (2017) Efficacy and safety of bispecific T-cell engager blinatumomab and the potential to improve leukemia-free survival in B-cell acute lymphoblastic leukemia. Expert Review of Hematology 10:12, pages 1057-1067.
Read now

Articles from other publishers (10)

Carmen Avendaño & J. Carlos Menéndez. 2023. Medicinal Chemistry of Anticancer Drugs. Medicinal Chemistry of Anticancer Drugs 1 35 .
Susanne H. C. Baumeister, Gopi S. Mohan, Alaa Elhaddad & Leslie Lehmann. (2022) Cytokine Release Syndrome and Associated Acute Toxicities in Pediatric Patients Undergoing Immune Effector Cell Therapy or Hematopoietic Cell Transplantation. Frontiers in Oncology 12.
Crossref
Katarzyna Pawinska-Wasikowska, Aleksandra Wieczorek, Walentyna Balwierz, Karolina Bukowska-Strakova, Marta Surman & Szymon Skoczen. (2022) Blinatumomab as a Bridge Therapy for Hematopoietic Stem Cell Transplantation in Pediatric Refractory/Relapsed Acute Lymphoblastic Leukemia. Cancers 14:2, pages 458.
Crossref
Manon Queudeville, Patrick Schlegel, Amadeus T. Heinz, Teresa Lenz, Michaela Döring, Ursula Holzer, Ulrike Hartmann, Hermann Kreyenberg, Arend von Stackelberg, Martin Schrappe, Gerhard Zugmaier, Tobias Feuchtinger, Peter Lang, Rupert Handgretinger & Martin Ebinger. (2021) Blinatumomab in pediatric patients with relapsed/refractory B‐cell precursor acute lymphoblastic leukemia. European Journal of Haematology 106:4, pages 473-483.
Crossref
Richard Thomas Layer. 2021. Remington. Remington 683 697 .
Omima Mustafa, Khalid Abdalla, Aeshah A AlAzmi, Naglla Elimam, Mohammed Burhan Abrar & Wasil Jastaniah. (2018) FLAG/FLAG-IDA regimen for children with relapsed/refractory acute leukemia in the era of targeted novel therapies. Journal of Oncology Pharmacy Practice 25:8, pages 1831-1838.
Crossref
Kate L. Lowe, David Cole, Rupert Kenefeck, Ita OKelly, Marco Lepore & Bent K. Jakobsen. (2019) Novel TCR-based biologics: mobilising T cells to warm ‘cold’ tumours. Cancer Treatment Reviews 77, pages 35-43.
Crossref
Rachel Salzman, Francesca Cook, Timothy Hunt, Harry L. Malech, Philip Reilly, Betsy Foss-Campbell & David Barrett. (2018) Addressing the Value of Gene Therapy and Enhancing Patient Access to Transformative Treatments. Molecular Therapy 26:12, pages 2717-2726.
Crossref
Juan Montoro, José L. Piñana, Jaime Sanz & Manuel Guerreiro. (2018) T lymphocytes as therapeutic arsenal for patients with hematological malignancies. Current Opinion in Oncology 30:6, pages 425-434.
Crossref
E. A. Vasilenko, V. V. Mokhonov, E. N. Gorshkova & I. V. Astrakhantseva. (2018) Bispecific Antibodies: Formats and Areas of Application. Molecular Biology 52:3, pages 323-334.
Crossref

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.